You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 20, 2025

Details for Patent: 11,285,098


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 11,285,098 protect, and when does it expire?

Patent 11,285,098 protects ZELSUVMI and is included in one NDA.

This patent has seventeen patent family members in seven countries.

Summary for Patent: 11,285,098
Title:Topical compositions and methods of using the same
Abstract:The present invention relates generally to compositions and methods of using the same.
Inventor(s):Doxey Ryan, Sabouni Adam, Kougoulos Eleftherios, Stasko Nathan
Assignee:Novan, Inc.
Application Number:US16267738
Patent Claim Types:
see list of patent claims
 
Patent landscape, scope, and claims:

Understanding the Scope and Claims of United States Patent 11,285,098: A Detailed Analysis

Introduction

When analyzing a patent, particularly one as complex as United States Patent 11,285,098, it is crucial to delve into the scope, claims, and the broader patent landscape. This article will provide a comprehensive overview of these aspects, using recent updates and guidelines from the U.S. Patent and Trademark Office (USPTO) as a framework.

The USPTO and Patent Eligibility

The USPTO plays a pivotal role in granting patents and registering trademarks in the United States. Recent updates, such as the 2024 USPTO Guidance on AI Patent Eligibility, have significant implications for innovators and patent practitioners[1].

Patent Eligibility Criteria

To understand the scope of any patent, including 11,285,098, one must consider the criteria for patent eligibility. The 2024 USPTO guidance emphasizes the importance of integrating judicial exceptions into practical applications. This involves assessing whether additional elements in the claim impose meaningful limits on the exception, thereby transforming the claim into patent-eligible subject matter[1].

AI-Assisted Inventions

The update clarifies that the method of invention development, including the use of AI, does not impact subject matter eligibility. Instead, the focus remains on the claimed invention itself, ensuring that AI-assisted inventions are evaluated on equal footing with other technologies. This distinction is crucial as it ensures that AI’s role as a tool does not exclude inventions from eligibility, provided there is significant human contribution[1].

Practical Applications and Real-World Benefits

Highlighting the real-world applications of the claimed method or system is vital for patent eligibility. Demonstrating how the abstract idea is applied in a way that provides concrete benefits or solves specific problems in the relevant field is essential. For example, a claim that merely uses a mathematical model to manipulate data without applying the data in any specific manner would not be patent-eligible. However, a claim that specifies the use of the data in a real-time system to enhance functionality would meet the criteria for patent eligibility[1].

Claim Structure and Examples

The 2024 guidance provides several examples of patent-eligible and ineligible claims. For instance, Claim 1 might involve routine data processing steps that are mere “insignificant extra-solution activity,” while Claim 2 includes additional steps that specify the use of separated audio components in a real-time speech recognition system, thereby providing a tangible outcome that directly benefits the technology[1].

Determining Inventorship

In addition to the scope and claims, determining the true and only inventors is a critical aspect of patent law. US patent law requires that whoever “invents” patentable subject matter is entitled to a patent. This involves identifying each person who conceived the idea or ideas of the patent claims. Conception is defined as the formation in the mind of the inventor of a definite and permanent idea of the complete and operative invention[5].

Patent Claims Research Dataset

For a deeper analysis, the USPTO's Patent Claims Research Dataset can be invaluable. This dataset contains detailed information on claims from U.S. patents granted between 1976 and 2014 and U.S. patent applications published between 2001 and 2014. It provides claim-level statistics and document-level statistics, which can help in understanding the scope and breadth of patent claims[3].

Economic and Statistical Analysis

Economic research and statistical analysis can also shed light on the patent landscape. Studies have shown that the probability of receiving a U.S. patent varies based on several factors, including the technology field, the origin of the application, and whether the applicant is a large or small entity. These analyses can help in understanding the broader context in which a patent like 11,285,098 operates[4].

Real-World Applications and Benefits

To illustrate the practical implications, let's consider a hypothetical example similar to those provided in the 2024 USPTO guidance. If Patent 11,285,098 involves a method for improving speech recognition accuracy using AI, the claims must specify how this method is applied in a real-world setting. For instance, if the patent claims the use of AI to separate audio components and enhance voice command accuracy in hands-free environments, it would need to demonstrate how this application provides concrete benefits, such as improved accuracy and functionality in speech recognition systems[1].

Incorporation of Recent Case Law

The 2024 guidance also incorporates recent case law, which is crucial for understanding the evolving landscape of patent eligibility. By referencing specific cases, practitioners can better draft claims that meet the criteria for patent eligibility. This ensures that the claimed invention offers a concrete technological improvement and is not merely an abstract idea[1].

Key Takeaways for Patent Practitioners

  • Focus on Practical Applications: Ensure that claims integrate judicial exceptions into practical applications.
  • AI-Assisted Inventions: The use of AI in invention development does not impact subject matter eligibility.
  • Real-World Benefits: Highlight how the claimed method or system provides concrete benefits or solves specific problems.
  • Claim Structure: Use examples from the 2024 guidance to craft claims that meet patent eligibility criteria.
  • Inventorship: Correctly determine and list the true and only inventors to ensure the patent's enforceability.

FAQs

Q: How does the 2024 USPTO guidance impact AI-related patent applications? A: The guidance clarifies that the method of invention development, including the use of AI, does not impact subject matter eligibility. It emphasizes the importance of integrating judicial exceptions into practical applications.

Q: What is the significance of specifying real-world applications in patent claims? A: Specifying real-world applications helps demonstrate how the abstract idea is applied in a way that provides concrete benefits or solves specific problems, thereby meeting the criteria for patent eligibility.

Q: How is inventorship determined in U.S. patent law? A: Inventorship is determined by identifying each person who conceived the idea or ideas of the patent claims. Conception is defined as the formation in the mind of the inventor of a definite and permanent idea of the complete and operative invention.

Q: What resources are available for analyzing patent claims and scope? A: The USPTO's Patent Claims Research Dataset and economic research studies provide valuable insights into patent claims and the broader patent landscape.

Q: Why is it important to incorporate recent case law in patent drafting? A: Incorporating recent case law helps ensure that claims are drafted in a manner that meets the evolving criteria for patent eligibility, thereby reducing the likelihood of section 101 rejections.

Key Takeaways

  • The 2024 USPTO guidance on AI patent eligibility refines the process for determining patent eligibility.
  • Practical applications and real-world benefits are crucial for patent eligibility.
  • AI-assisted inventions are evaluated on equal footing with other technologies.
  • Correct inventorship is essential for the enforceability of a patent.
  • Recent case law and economic research datasets are valuable resources for patent practitioners.

Sources

  1. Understanding the 2024 USPTO Guidance Update on AI Patent - Mintz.
  2. U.S. Patent and Trademark Office (USPTO) - USA.gov.
  3. Patent Claims Research Dataset - USPTO.
  4. What Is the Probability of Receiving a US Patent? - YJOLT.
  5. Determining Inventorship for US Patent Applications - Oregon State University.

More… ↓

⤷  Try for Free


Drugs Protected by US Patent 11,285,098

ApplicantTradenameGeneric NameDosageNDAApproval DateTETypeRLDRSPatent No.Patent ExpirationProductSubstanceDelist Req.Patented / Exclusive UseSubmissiondate
Lnhc ZELSUVMI berdazimer sodium GEL;TOPICAL 217424-001 Jan 5, 2024 RX Yes Yes ⤷  Try for Free ⤷  Try for Free Y ⤷  Try for Free
>Applicant>Tradename>Generic Name>Dosage>NDA>Approval Date>TE>Type>RLD>RS>Patent No.>Patent Expiration>Product>Substance>Delist Req.>Patented / Exclusive Use>Submissiondate
Showing 1 to 1 of 1 entries

International Family Members for US Patent 11,285,098

CountryPatent NumberEstimated ExpirationSupplementary Protection CertificateSPC CountrySPC Expiration
Australia 2014223164 ⤷  Try for Free
Brazil 112015019657 ⤷  Try for Free
Canada 2900557 ⤷  Try for Free
Canada 3133526 ⤷  Try for Free
>Country>Patent Number>Estimated Expiration>Supplementary Protection Certificate>SPC Country>SPC Expiration
Showing 1 to 4 of 4 entries

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.